Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 2/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21374325 | 0.84 | KDM4C (0.41) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL28678179 | 0.74 | MEN1 (0.47) | MEN1KMT2AKDM4CL3MBTL1TACR1 | |
| SCHEMBL21326191 | 0.74 | MEN1 (0.35) | MEN1KMT2AKDM4CL3MBTL1TACR1 | |
| SCHEMBL18636430 | 0.73 | MEN1 (0.40) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL18614980 | 0.71 | MEN1 (0.41) | MEN1KMT2AKDM4CL3MBTL1TACR1 | |
| SCHEMBL18614963 | 0.69 | MEN1 (0.41) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL21217168 | 0.65 | KDM4C (0.41) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL21659773 | 0.65 | KDM4C (0.41) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL21217167 | 0.63 | KDM4C (0.42) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL18615095 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922437-B | Bridged piperidine derivatives | 豪夫迈·罗氏有限公司 | 2021-12-10 | — | — | CN | disclosed |
| US-10604517-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10604517-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20180237432-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-08-23 | — | — | US | disclosed |
| EP-3347363-A1 | BRIDGED PIPERIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-07-18 | — | — | EP | disclosed |
| WO-2017042114-A1 | BRIDGED PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017042114-A1 | BRIDGED PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237432-A1 | BRIDGED PIPERIDINE DERIVATIVES | HPGDS, APP, PSEN1 | MEN1 2472/4885KMT2A 1370/4885KDM4C 3966/4885 |
| US-10604517-B2 | Bridged piperidine derivatives | HPGDS, APP, PSEN1 | MEN1 2472/4885KMT2A 1370/4885KDM4C 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.